» Articles » PMID: 29601840

Protein Nanoparticles Promote Microparticle Formation in Intravenous Immunoglobulin Solutions During Freeze-Thawing and Agitation Stresses

Overview
Journal J Pharm Sci
Publisher Elsevier
Specialties Pharmacology
Pharmacy
Date 2018 Mar 31
PMID 29601840
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

In this study, we investigated the potential roles of nanoparticles (<100 nm) and submicron (100-1000 nm) particles in the formation of microparticles (>1000 nm) in protein formulations under some pharmaceutically relevant stress conditions. Exposure of intravenous immunoglobulin solutions to the interface-associated stresses of freeze-thawing or agitation resulted in relatively large increases in microparticle concentrations, which depended directly on the levels of pre-existing nano- and submicron particles. Thus, agglomeration of nanoparticles and submicron particles appears to play a role in microparticle formation under these stresses. In contrast, increases in microparticle concentrations during quiescent incubation at elevated temperatures were independent of the initial nano- and submicron particle concentrations in solution.

Citing Articles

Enhancing chemical and physical stability of pharmaceuticals using freeze-thaw method: challenges and opportunities for process optimization through quality by design approach.

Bernal-Chavez S, Romero-Montero A, Hernandez-Parra H, Pena-Corona S, Del Prado-Audelo M, Alcala-Alcala S J Biol Eng. 2023; 17(1):35.

PMID: 37221599 PMC: 10207779. DOI: 10.1186/s13036-023-00353-9.


Subvisible Particles in IVIg Formulations Activate Complement in Human Serum.

Chisholm C, Behnke W, Pokhilchuk Y, Frazer-Abel A, Randolph T J Pharm Sci. 2019; 109(1):558-565.

PMID: 31672401 PMC: 6948146. DOI: 10.1016/j.xphs.2019.10.041.

References
1.
Barnard J, Singh S, Randolph T, Carpenter J . Subvisible particle counting provides a sensitive method of detecting and quantifying aggregation of monoclonal antibody caused by freeze-thawing: insights into the roles of particles in the protein aggregation pathway. J Pharm Sci. 2010; 100(2):492-503. DOI: 10.1002/jps.22305. View

2.
Corvari V, Narhi L, Spitznagel T, Afonina N, Cao S, Cash P . Subvisible (2-100 μm) particle analysis during biotherapeutic drug product development: Part 2, experience with the application of subvisible particle analysis. Biologicals. 2015; 43(6):457-73. DOI: 10.1016/j.biologicals.2015.07.011. View

3.
Tyagi A, Randolph T, Dong A, Maloney K, Hitscherich Jr C, Carpenter J . IgG particle formation during filling pump operation: a case study of heterogeneous nucleation on stainless steel nanoparticles. J Pharm Sci. 2008; 98(1):94-104. DOI: 10.1002/jps.21419. View

4.
Saller V, Matilainen J, Grauschopf U, Bechtold-Peters K, Mahler H, Friess W . Particle shedding from peristaltic pump tubing in biopharmaceutical drug product manufacturing. J Pharm Sci. 2015; 104(4):1440-50. DOI: 10.1002/jps.24357. View

5.
Joubert M, Hokom M, Eakin C, Zhou L, Deshpande M, Baker M . Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses. J Biol Chem. 2012; 287(30):25266-79. PMC: 3408134. DOI: 10.1074/jbc.M111.330902. View